Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NELARABINE vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
T-cell acute lymphoblastic leukemia (T-ALL),T-cell lymphoblastic lymphoma (T-LBL),Relapsed or refractory T-ALL/T-LBL
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, which is then phosphorylated to ara-GTP intracellularly. It is partially metabolized by aldehyde oxidase.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
<25% bound to plasma proteins (albumin).
Approximately 20–30% bound to plasma proteins.
Vd: 197 L/m² (approx 5.6 L/kg based on 1.73 m²/70 kg), indicating extensive tissue distribution.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
IV only; oral bioavailability not established (<5% due to extensive first-pass metabolism).
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Cr Cl 30-60 m L/min: reduce dose to 975 mg/m2. Cr Cl <30 m L/min: not recommended.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh Class B or C: reduce dose to 975 mg/m2. No data for severe impairment.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
650 mg/m2 intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended; monitor renal function and hematologic toxicity closely.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
Severe neurotoxicity, including Guillain-Barré-like syndrome, peripheral neuropathy, and CNS demyelination. Avoid in patients with severe pre-existing neurological conditions.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Monitor for neurological toxicity; may require discontinuation.,Hematologic toxicity: neutropenia, thrombocytopenia, anemia.,Increased risk of infection.,Tumor lysis syndrome prophylaxis required.,Hepatotoxicity and renal toxicity.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to nelarabine or its components.,Severe pre-existing neurological disorders (e.g., Guillain-Barré syndrome, peripheral neuropathy).,Pregnancy (may cause fetal harm).
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice? No evidence for interaction.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk of congenital malformations, intrauterine growth restriction, and fetal death. Use during the first trimester carries highest risk of major malformations; second and third trimester exposure may cause myelosuppression and low birth weight. Avoid in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No human data on nelarabine excretion in breast milk. Due to its mechanism of action (DNA synthesis inhibition) and potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during therapy and for at least 3 months after the last dose.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No established dose adjustments in pregnancy. Physiological changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may alter nelarabine pharmacokinetics, but no specific studies exist. Use standard weight-based dosing with careful monitoring for toxicity. Consider reducing dose if severe myelosuppression or neurotoxicity occurs.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Administer intravenously over 2 hours. Monitor for neurological toxicity including somnolence, ataxia, and seizures. Premedicate with antiemetics. Use in T-cell acute lymphoblastic leukemia/lymphoma after failure of two prior regimens. Contraindicated in severe renal impairment (Cr Cl <30 m L/min).
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This drug can cause severe drowsiness and coordination problems; do not drive or operate machinery until you know how it affects you.,Report any unusual tiredness, muscle weakness, or tingling in hands/feet to your doctor immediately.,If you experience seizures, loss of consciousness, or confusion, seek emergency medical attention.,You will have regular blood tests to monitor your blood cell counts and kidney function.,This drug can cause serious infections; wash hands frequently and avoid crowds.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not receive live vaccines during therapy without consulting your doctor.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
"Roflumilast may increase the immunosuppressive activities of Nelarabine."
"The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine."
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NELARABINE vs CLADRIBINE, answered by our medical review team.
NELARABINE is a Antineoplastic Agent that works by Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NELARABINE and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NELARABINE is: 1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NELARABINE and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NELARABINE is classified as Category C. Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.